Press release
Respiratory Syncytial Virus Pipeline Insight: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Therapeutic Analysis, Growth Prospects, and Companies by DelveInsight
Respiratory Syncytial Virus Pipeline
Request a sample and discover the recent breakthroughs happening in the Respiratory Syncytial Virus pipeline landscape @ https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Respiratory Syncytial Virus Pipeline Report
• DelveInsight's Respiratory Syncytial Virus Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Respiratory Syncytial Virus treatment.
• Leading Respiratory Syncytial Virus companies in the market are GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
• Promising Respiratory Syncytial Virus pipeline therapies in various stages of development include Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others.
• In May 2023, GSK announced the clearance of Arexvy, a vaccine against the respiratory syncytial virus (RSV), by the US Food and Drug Administration, making it the world's first vaccination of its kind.
• In May 2023, Ascletis Pharma Inc. reported that the China National Medical Products Administration ("NMPA") has approved a Phase IIa clinical trial for ASC10 to treat respiratory syncytial virus (RSV) infection.
Respiratory Syncytial Virus Overview
Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection, especially in youngsters. By the age of four, nearly all children have been infected, with many infected during their first year of life. Because infection does not offer complete immunity, reinfection is common, albeit usually less severe. Outbreaks are most common in the winter and early spring. RSV is the most prevalent cause of lower respiratory tract infection in young infants, accounting for more than 50,000 hospitalizations in children under the age of five in the United States each year. The initial infection frequently proceeds from an upper respiratory tract disease with congestion and fever to the lower respiratory tract, causing bronchiolitis and, in rare cases, pneumonia with cough and difficulty breathing. Later infections often exclusively affect the upper respiratory tract. Children who have suffered bronchiolitis are more prone to develop asthma as they grow older.
Find out more about Respiratory Syncytial Virus medication @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Respiratory Syncytial Virus Treatment Analysis: Drug Profile
Nirsevimab (MEDI-8897): MedImmune
MEDI8897 is a monoclonal antibody (mAb) used to prevent lower respiratory tract sickness (LRTI) caused by respiratory syncytial virus (RSV), which is the most common cause of LRTI in newborns and young children. It is currently in phase III of development.
Sisunatovir: ReViral
Sisunatovir is an orally given fusion inhibitor that works by preventing RSV F-mediated fusion with the host cell. Preclinical studies revealed that sisunatovir has a low toxicity profile and a promising therapeutic index. Sisunatovir demonstrated excellent exposure in Phase 1 clinical investigations, with no significant side effects recorded. In 2018, the findings of Phase 2a challenge research in healthy adult volunteers revealed that sisunatovir reduced viral load and clinical symptoms statistically significantly. ReViral has begun two international multicenter Phase 2 clinical trials of sisunatovir in high-risk pediatric and adult patient populations.
Key Respiratory Syncytial Virus Therapies and Companies
• Nirsevimab (MEDI-8897): MedImmune
• Sisunatovir: ReViral
• MVA-BN-RSV Vaccine: Bavarian Nordic
• RSVpreF (PF-06928316): Pfizer
• VAC 18193 (Ad26.RSV.preF): Janssen
• mRNA-1345: Moderna
Learn more about the novel and emerging Respiratory Syncytial Virus pipeline therapies @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Respiratory Syncytial Virus Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy
By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample Report @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Respiratory Syncytial Virus Pipeline Report
• Coverage: Global
• Key Respiratory Syncytial Virus Companies: GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.
• Key Respiratory Syncytial Virus Pipeline Therapies: Nirsevimab (MEDI-8897), Sisunatovir, RSV F protein vaccine, Novavax, Combination seasonal influenza RSV nanoparticle vaccine, NanoFlu/NVX CoV 2373/RSV, RSVpreF, SP 0125, BC-0004, GSK 3888550A, DPX RSV Vaccine, AR 201, ASCENIV, EDP 938, MK 1654, Rilematovir, GSK 3003891A, JNJ 64400141, Ziresovir, JNJ 64213175, MV-012-968, ALS-008176, CodaVax-RSV, BARS13, MVA-BN-RSV, mRNA-1345, V-306, ALVR106, AR-201, AT-889, ATR-002, IVX-121, RBS-3149, and others.
Dive deep into rich insights for drugs used for Respiratory Syncytial Virus treatment; visit @ https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight
Table of Contents
1. Introduction
2. Executive Summary
3. Respiratory Syncytial Virus Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Respiratory Syncytial Virus Pipeline Therapeutics
6. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
7. Respiratory Syncytial Virus Pipeline: Late Stage Products (Phase III)
8. Respiratory Syncytial Virus Pipeline: Mid-Stage Products (Phase II)
9. Respiratory Syncytial Virus Pipeline: Early Stage Products (Phase I)
10. Respiratory Syncytial Virus Therapeutic Assessment
11. Inactive Respiratory Syncytial Virus Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Respiratory Syncytial Virus Companies
14. Key Respiratory Syncytial Virus Products
15. Respiratory Syncytial Virus Unmet Needs
16. Respiratory Syncytial Virus Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Trending Reports:
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/palmar-hyperhidrosis-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Buerger's Disease Pipeline Insight: https://www.delveinsight.com/sample-request/buergers-disease-pipeline-insight
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus Pipeline Insight: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Therapeutic Analysis, Growth Prospects, and Companies by DelveInsight here
News-ID: 3355688 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Respiratory
Prevalence Of Respiratory Diseases Fuels Demand For Respiratory Disposables: Key …
The Respiratory Disposables Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Respiratory Disposables Market Size During the Forecast Period?
The respiratory disposables market has seen rapid growth in recent years. It is expected to grow from $1.01 billion in 2024 to $1.15…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Transforming the Respiratory Monitoring Devices Market in 2025: Rising Incidence …
What Is the Expected Size and Growth Rate of the Respiratory Monitoring Devices Market?
The market size for respiratory monitoring devices has seen swift expansion in the recent past. The market's growth is projected to increase from $1.67 billion in 2024 to $1.87 billion in 2025, with a compound annual growth rate (CAGR) of 11.8%. A combination of factors such as the prevalence of respiratory ailments, an aging demographic, technological innovations,…
Molecular Respiratory Panels Market: Enhancing Accuracy and Speed in Respiratory …
Introduction
The global molecular respiratory panels market is rapidly evolving, driven by the need for faster, more accurate diagnostics in respiratory diseases. With respiratory infections and diseases becoming increasingly prevalent worldwide, accurate detection and timely diagnosis are critical to improving patient outcomes. Molecular respiratory panels, which utilize advanced molecular techniques like PCR (Polymerase Chain Reaction) and other nucleic acid-based methods, enable the rapid identification of pathogens responsible for respiratory conditions. These…
Tackling Respiratory Challenges: Lower Respiratory Tract Therapeutics Market 202 …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Lower Respiratory Tract Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $48.37 billion In…
Respiratory Assist Devices Market - Breathing Uninterrupted: Innovating Respirat …
Newark, New Castle, USA - new report, titled Respiratory Assist Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Respiratory Assist Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Respiratory Assist Devices market. The report offers an overview of…
